NVCR
NovoCure Limited
NVCR's outlook is improving, though it still trails on the overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over NVCR overall, supported by stronger fundamentals and lower modeled downside.
NVCR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Strong |
NVCR's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
NVCR PE Valuation
NVCR has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
NVCR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect NVCR's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
NVCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.06 | +$0.55 |
| Q2 2026 | -$1.30 | +$0.26 |
| Q1 2026 | -$1.53 | -$0.02 |
| Q4 2025 | -$1.22 | +$0.34 |
| Q3 2025 | -$1.61 | -$0.21 |
| Q2 2025 | -$1.56 | +$0.02 |
| Q1 2025 | -$1.51 | +$0.30 |
| Q4 2024 | -$1.56 | +$0.39 |
NVCR is still losing money, but less than at its worst: $1.06 per share over the past year, against $1.95 at its worst in late 2023.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over NVCR on earnings quality, reporting a profit while its opponent remains loss making.
NVCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $193.4M | +16% |
| Q2 2026 | $183.6M | +16% |
| Q1 2026 | $174.1M | +12% |
| Q4 2025 | $174.4M | +8.1% |
| Q3 2025 | $167.2M | +7.8% |
| Q2 2025 | $158.8M | +5.6% |
| Q1 2025 | $155M | +12% |
| Q4 2024 | $161.3M | +21% |
NVCR's revenue has grown year over year for 12 quarters in a row: $193M last quarter, up 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3.2% | +18 points |
| Q2 2026 | -5.8% | +19 points |
| Q1 2026 | -39% | -14 points |
| Q4 2025 | -23% | +16 points |
| Q3 2025 | -22% | -0.8 points |
| Q2 2025 | -25% | -2.6 points |
| Q1 2025 | -24% | +5.6 points |
| Q4 2024 | -39% | -0.6 points |
NVCR's operating margin was −3.2% last quarter, up 18 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over NVCR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over NVCR on profitability, with a higher operating margin.
NVCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $15.7M | +5.5% |
| Q2 2026 | $1.2M | +$22.6M |
| Q1 2026 | -$18.7M | +$27.6M |
| Q4 2025 | -$22.9M | -$10.5M |
| Q3 2025 | $14.9M | +$15.2M |
| Q2 2025 | -$21.4M | -$8.3M |
| Q1 2025 | -$46.3M | -$2.9M |
| Q4 2024 | -$12.4M | +$9M |
NVCR's free cash flow was −$25M over the past year, against −$65M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over NVCR on cash generation, producing positive trailing cash flow while its opponent burns cash.
NVCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +773K shares |
| 1 year | +4.4% | +4.9M shares |
| 3 years | +9.4% | +10M shares |
| 5 years | +13% | +13.1M shares |
| Available history | +8.2% | +8.9M shares |
NVCR has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NVCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2021 | -105.8x | Net Cash |
| Q2 2021 | 8.7x | High |
| Q1 2021 | 5.7x | High |
| Q4 2020 | 4.9x | High |
| Q3 2020 | -8.5x | Net Cash |
| Q2 2020 | -2.9x | Net Cash |
| Q1 2020 | -3.2x | Net Cash |
| Q4 2019 | -3.7x | Net Cash |
NVCR has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
NVCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.6 | Neutral |
| Stochastic | 14.2 | Oversold |
NVCR's weekly RSI is 38 (neutral) and its Stochastic is 14 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
NVCR PE vs Healthcare Sector
| Metric | NVCR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NVCR has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NVCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $14.0 | 16% below |
| 20 week MA | $15.6 | 25% below |
| 50 week MA | $14.5 | 19% below |
| 100 week MA | $16.0 | 27% below |
| 200 week MA | $23.3 | 50% below |
NVCR is in a downtrend: it's below all five of its weekly moving averages, and 50% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over NVCR on trend strength, trading above more of its moving averages.
NVCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $87.6 | $172.0 | +96% |
| 2021 | $172.0 | $84.0 | -51% |
| 2022 | $84.0 | $73.0 | -13% |
| 2023 | $73.0 | $14.9 | -80% |
| 2024 | $14.9 | $30.7 | +106% |
| 2025 | $30.7 | $13.5 | -56% |
| 2026 YTD | $13.5 | $11.7 | -13% |
NVCR's yearly returns have swung widely, from +106% in 2024 to −80% in 2023. It's down 13% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over NVCR on returns for 2026, with the stronger performance.